by June Kinoshita, Director of Research and Patient Engagement Fulcrum’s announcement that it will proceed with a Phase 3 clinical trial of losmapimod is big news for the FSHD community…. Read More »
Fulcrum’s Phase 3 trial news – what does it mean for patients?
Fulcrum announces Phase 3 trial of losmapimod
From Fulcrum Therapeutics’ press release Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022 Potential first-to-market therapy for… Read More »
Teen with FSHD is in top 40 of Science Talent Search
Our very own Heloise Hoffmann, leader of the Southwest Florida chapter and Walk & Roll, is a science rock star! The Society for Science named her a top 40 finalist… Read More »
FSHD Canada Foundation awards $2.8 million to CTRN
by June Kinoshita, FSHD Society The FSHD Canada Foundation, a close partner and fellow traveler of the FSHD Society since its founders Neil Camarta and Craig Kelley first met in… Read More »
Extraordinary Measures – Understanding the socioeconomic impact of FSHD
An aspect that is often overlooked during drug development is a cost-benefit analysis of a therapeutic treatment. Insurance companies often determine the level of coverage they are willing to provide… Read More »